Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8(+) T cells through reduction of tumor-associated macrophage and activation of the interferon pathway

Lenvatinib is a multiple receptor tyrosine kinase inhibitor targeting mainly vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) receptors. We investigated the immunomodulatory activities of lenvatinib in the tumor microenvironment and its mechanisms of enhanced antitumor ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Yu, Tabata, Kimiyo, Kimura, Takayuki, Yachie-Kinoshita, Ayako, Ozawa, Yoichi, Yamada, Kazuhiko, Ito, Junichi, Tachino, Sho, Hori, Yusaku, Matsuki, Masahiro, Matsuoka, Yukiko, Ghosh, Samik, Kitano, Hiroaki, Nomoto, Kenichi, Matsui, Junji, Funahashi, Yasuhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392299/
https://www.ncbi.nlm.nih.gov/pubmed/30811474
http://dx.doi.org/10.1371/journal.pone.0212513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392299/
https://www.ncbi.nlm.nih.gov/pubmed/30811474
http://dx.doi.org/10.1371/journal.pone.0212513

Ejemplares similares